Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,486.40
(
0.32%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
92.41
(
0.00%
)
Bitcoin
72,965.52
(
-0.02%
)
News Focus
News Focus
Post# of 257382
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

north40000

Send PM Follow Ignore
Followers 269
Posts 18893
Boards Moderated 0
Alias Born 01/19/2006

north40000

Member Level

Re: DewDiligence post# 83346

Wednesday, 09/09/2009 5:54:01 PM

Wednesday, September 09, 2009 5:54:01 PM

Post# of 257382
VVUS


>>Qnexa (Q-NEX-uh) is a once-a-day, proprietary, oral, controlled-release formulation of low dose phentermine and topiramate.<<

Typical formulators of the 2 generics might not duplicate the controlled-release feature described above. I have no current idea whether that is a feature of the claims of any patent VVUS may have, or whether controlled-release is critical to the purported safety[and efficacy] of the product.
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today